Significantly lower risk is seen for recovery and viral clearance. 2 studies from 2 independent teams (both from the same country) show significant benefit.
Meta analysis using the most serious outcome reported shows 11% [-1‑21%] lower risk, without reaching statistical significance. Results are better for Randomized Controlled Trials.
Currently there is limited data, with only 1 control event for the most serious outcome in trials to date. Studies to date are from only 2 different groups.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.
Zheng et al. present another meta analysis for deuremidevir, showing significant improvement for viral clearance.
Covid Analysis et al., Dec 2024, preprint, 1 author.
